Interferons (IFNs) are crucial in the host's antiviral defense, inducing an antiviral state through the expression of IFN-stimulated genes (ISGs). However, viruses have evolved mechanisms to counteract IFN responses, hindering their effectiveness. This review explores the complex interactions between IFNs and four significant viruses—flu, hepatitis C, herpes simplex, and vaccinia—to highlight the diversity of viral strategies. Understanding these interactions is vital for developing new therapeutic interventions. Recent advances in functional genomics, bioinformatics, and other technologies are aiding this effort. IFNs are divided into type I (IFN-α, IFN-β, IFN-ω, IFN-τ) and type II (IFN-γ). Type I IFNs are produced by many cells, while IFN-γ is produced by immune cells. IFNs act through specific receptors, triggering signaling pathways that lead to the expression of hundreds of ISGs. These ISGs play a key role in the antiviral state, but viruses have developed strategies to block IFN signaling, including inhibiting IFN receptors, disrupting signaling pathways, and downregulating ISG expression. Viruses like influenza and hepatitis C have evolved to counteract IFN responses. Influenza virus, for example, uses the NS1 protein to inhibit PKR, a key antiviral enzyme. Hepatitis C virus (HCV) has a complex relationship with IFNs, with certain genotypes showing resistance due to mutations in the NS5A region. HCV also adapts to host defenses by selecting mutations that confer resistance to IFN. Herpes simplex virus (HSV) interacts with IFNs by modulating the IFN system and PKR. HSV1 can disrupt the IFN response by blocking the JAK-STAT pathway and downregulating ISGs. Vaccinia virus, a poxvirus, encodes soluble IFN receptors that block IFN signaling and inhibits PKR, helping the virus evade host defenses. The study of virus-host interactions is being advanced by functional genomics and bioinformatics, which help identify new therapeutic targets. These technologies are crucial for understanding how viruses evade host defenses and for developing more effective antiviral therapies. The integration of data from various virus-host systems is expected to provide insights into common pathways and strategies, aiding in the development of new treatments for viral infections.Interferons (IFNs) are crucial in the host's antiviral defense, inducing an antiviral state through the expression of IFN-stimulated genes (ISGs). However, viruses have evolved mechanisms to counteract IFN responses, hindering their effectiveness. This review explores the complex interactions between IFNs and four significant viruses—flu, hepatitis C, herpes simplex, and vaccinia—to highlight the diversity of viral strategies. Understanding these interactions is vital for developing new therapeutic interventions. Recent advances in functional genomics, bioinformatics, and other technologies are aiding this effort. IFNs are divided into type I (IFN-α, IFN-β, IFN-ω, IFN-τ) and type II (IFN-γ). Type I IFNs are produced by many cells, while IFN-γ is produced by immune cells. IFNs act through specific receptors, triggering signaling pathways that lead to the expression of hundreds of ISGs. These ISGs play a key role in the antiviral state, but viruses have developed strategies to block IFN signaling, including inhibiting IFN receptors, disrupting signaling pathways, and downregulating ISG expression. Viruses like influenza and hepatitis C have evolved to counteract IFN responses. Influenza virus, for example, uses the NS1 protein to inhibit PKR, a key antiviral enzyme. Hepatitis C virus (HCV) has a complex relationship with IFNs, with certain genotypes showing resistance due to mutations in the NS5A region. HCV also adapts to host defenses by selecting mutations that confer resistance to IFN. Herpes simplex virus (HSV) interacts with IFNs by modulating the IFN system and PKR. HSV1 can disrupt the IFN response by blocking the JAK-STAT pathway and downregulating ISGs. Vaccinia virus, a poxvirus, encodes soluble IFN receptors that block IFN signaling and inhibits PKR, helping the virus evade host defenses. The study of virus-host interactions is being advanced by functional genomics and bioinformatics, which help identify new therapeutic targets. These technologies are crucial for understanding how viruses evade host defenses and for developing more effective antiviral therapies. The integration of data from various virus-host systems is expected to provide insights into common pathways and strategies, aiding in the development of new treatments for viral infections.